FDA Approves Eflornithine for Adult and Pediatric Patients with HRNB

On December 13, the US Food and Drug Administration (FDA) approved eflornithine to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

For more information read the FDA announcement and the US WorldMeds announcement.

Posted 12/18/2023